公开(公告)号：US20250066487A1

公开(公告)日：2025-02-27

申请号：US18935875

申请日：2024-11-04

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung YONG ,  Ui-Jung JUNG ,  Hyejin CHUNG ,  Kyeongsu PARK ,  Wonjun SON ,  Yangsoon LEE ,  Yeunju KIM ,  Eunsil SUNG ,  Youngkwang KIM ,  Youngdon PAK ,  Minji PARK ,  Jaehyun EOM ,  Hyoju CHOI ,  Moo Young SONG ,  Na Rae LEE ,  Young Bong PARK ,  Eun-Jung LEE ,  Eun-Jung LEE

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US20230002460A1

公开(公告)日：2023-01-05

申请号：US17779932

申请日：2020-11-25

Applicant: YUHAN CORPORATION

Inventor： Seyoung LIM ,  Young Bong PARK ,  Sukyung KIM ,  Bo Ra SIM ,  Wonee CHONG ,  Hyun Ho CHOI ,  Ji Eun YANG ,  Mi Kyeong JU ,  Won Tae KIM ,  Youn Woo LEE ,  Junhwan KIM

IPC: C07K14/475 ,  C12N15/63

Abstract: A fusion protein including a GDF15 variant having increased physiological activity and in vivo stability, and a pharmaceutical composition containing the same are disclosed. The GDF15 variant or long-acting GDF15 fusion protein is superior to conventional GDF15 variants in terms of in vitro efficacy, binding affinity for GDF15 receptors, and body weight loss effect. Therefore, a pharmaceutical composition containing, as an active ingredient, the GDF15 variant, the long-acting GDF15 fusion protein, or a dimer of the fusion protein, causes appetite suppression, and thus can be effectively used as a therapeutic agent for metabolic diseases or obesity. Furthermore, the pharmaceutical composition can be used in combination therapy or the like with chemical drugs and other therapeutic agents for metabolic diseases, and can be effectively used in combination therapy with conventional therapeutic agents for metabolic diseases or obesity.

公开(公告)号：US20210087268A1

公开(公告)日：2021-03-25

申请号：US16970351

申请日：2019-02-28

Applicant: YUHAN CORPORATION

Inventor： Kwang-Hoon LEE ,  June Hyung LEE ,  Na Rae LEE ,  Eunjeong JEONG ,  Young Bong PARK ,  Nakho CHANG ,  Eun-Jung LEE ,  Ki Hong KIM ,  Sunghyun CHOI ,  Byung Hyun CHOI ,  Ju Young PARK ,  Moo Young SONG ,  Jong-Seo LEE ,  Kyu-Tae KIM ,  Bong-Kook KO

IPC: C07K16/28

Abstract: Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition.
The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.